You just read:

The U.S. FDA Completed Pre-License Inspection (PLI) of WuXi Biologics cGMP Manufacturing Facilities for Production of TMB-355 (ibalizumab)

News provided by

WuXi AppTec

Aug 02, 2017, 21:23 ET